ChemicalBook--->CAS DataBase List--->1965291-08-0

1965291-08-0

1965291-08-0 Structure

1965291-08-0 Structure
IdentificationBack Directory
[Name]

Ibrexafungerp citrate
[CAS]

1965291-08-0
[Synonyms]

Ibrexafungerp citrate
[Molecular Formula]

C50H75N5O11
[MOL File]

1965291-08-0.mol
[Molecular Weight]

922.17
Chemical PropertiesBack Directory
[form ]

Solid
[color ]

White to off-white
Hazard InformationBack Directory
[Uses]

Ibrexafungerp citrate (MK 3118 citrate) is an orally active β-1,3-glucan synthesis inhibitor, with potential antifungal activity. Ibrexafungerp citrate is an investigational agent for the treatment of Candida and Aspergillus infections[1].
[in vivo]

Pharmacokinetic Analysis
Ibrexafungerp citrate (MK 3118 citrate) exhibits oral bioavailability (mouse 51%, rat 45%, dog 35%) following oral administration (mouse 1 mg/kg, rat 5 mg/kg and dog 5 mg/kg)[3].
Ibrexafungerp citrate (MK 3118 citrate) exhibits moderate half-lives (mouse 5.5, rat 8.7 and, dog 9.3 h) due to high plasma clearance (0.68, 0.44, and 0.45 L/h/kg respectively) combined with large volumes of distribution (5.3, 4.7, and 4.1 L/kg respectively) following intravenous administration (mouse 1 mg/kg, rat 5 mg/kg and dog 5 mg/kg)[3].

Animal Model:Female CD1 mice, Male and female Han Wister rats, Male and female beagle dogs[3]
Dosage:Mice (1 mg/kg), rats (5 mg/kg) and dogs (5 mg/kg)
Administration:Intravenous (i.v.) or oral gavage
Result:T1/2s of 5.5, 8.7, and 9.3 h for mice, rats, and dogs, respectively.
[References]

[1] James M Apgar, et al. Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor. Bioorg Med Chem Lett. 2021 Jan 15;32:127661. DOI:10.1016/j.bmcl.2020.127661
[2] Mahmoud Ghannoum, et al. Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections. Antibiotics (Basel). 2020 Aug 25;9(9):539. DOI:10.3390/antibiotics9090539
[3] Stephen A Wring, et al. Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02068-16. DOI:10.1128/AAC.02068-16
1965291-08-0 suppliers list
Company Name: Suzhou Biosyntech Co., Ltd
Tel: +86-13921151340
Website:
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Website: https://www.bocsci.com
Company Name: Wuhan Ruilida Biomedical Technology Co., Ltd.  
Tel: 18201884268
Website: www.chemicalbook.com/ShowSupplierProductsList31333/0_EN.htm
Company Name: Chengdu ruihede Medical Technology Co., Ltd  
Tel: 17381862311; 17381862311
Website: https://www.ruihede.cn
Company Name: Suzhou Biosyntech Co., Ltd.  
Tel: +86-0512-63001269 +86-13921151340
Website: www.biosyntech-suzhou.com/default.aspx
Company Name: Nantong Hi-Future Biotechnology Co., Ltd  
Tel: 18051384581
Website: https://www.chemhifuture.com/
Company Name: Xianning Shen Lan Biomedical Research and Development Co., Ltd.  
Tel: 18171815831
Website: http://www.shenlansw.com/
Company Name: Shanghai Tachizaki Biomedical Research Center  
Tel: 18014399201
Website: http://www.chemlab-tachizaki.com/
Company Name: Suzhou Haiben Pharmaceutical Co., Ltd  
Tel: 19353112242
Website:
Company Name: mahaloong  
Tel: +86-028-81192082 +86-18180560816
Website: https://www.mahaloong.com
Company Name: CDYXYL  
Tel: 13688280140
Website:
Tags:1965291-08-0 Related Product Information

  • HomePage | Member Companies | Advertising | Contact us | Previous WebSite | MSDS | CAS Index | CAS DataBase | Privacy | Terms | About Us
  • All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
    According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.
  • Copyright © 2023 ChemicalBook All rights reserved.